| Literature DB >> 25995149 |
Xiaoming Chen1, Shengguo Duan1, Cheng Tao2, Hongbin Zhai2, Fayang G Qiu3.
Abstract
The structurally complex alkaloid gelsemine was previously thought to have no significant biological activities, but a recent study has shown that it has potent and specific antinociception in chronic pain. While this molecule has attracted significant interests from the synthetic community, an efficient synthetic strategy is still the goal of many synthetic chemists. Here we report the asymmetric total synthesis of (+)-gelsemine, including a highly diastereoselective and enantioselective organocatalytic Diels-Alder reaction, an efficient intramolecular trans-annular aldol condensation furnishing the prolidine ring and establishing the configuration of the C20 quaternary carbon stereochemical centre. The entire gelsemine skeleton was constructed through a late-stage intramolecular SN2 substitution. The enantiomeric excess of this total synthesis is over 99%, and the overall yield is around 5%.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25995149 PMCID: PMC4647982 DOI: 10.1038/ncomms8204
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Figure 1The structures of gelsemium alkaloids.
The difference between the members of the gelsemium alkaloids is the presence of the functional groups in the unique carbon skeleton. The major difference appeared in C-19 and C-21.
Figure 2Schematic summary of the previous total syntheses of gelsemine.
Among the seven total syntheses completed so far, two of them were asymmetric and the overall yields were around 1%. This molecule has been an active target of total synthesis during the past two decades.
Figure 3Retrosynthetic analysis of gelsemine.
In principle, gelsemine may be constructed from oxindole and intermediate RS-1, where X is a leaving group. After a few transformations, RS-1 may be synthesized from intermediate RS-2, which inturn may be obtained from RS-3 following several reaction steps including ozonolysis. Finally, RS-3 may be synthesized from readily accessible starting materials.
Figure 4Cyclization of intermediate 9 to form the gelsemine framework.
This scheme illustrates the equilibrium between intermediates 12 and 12b via the formation of intermediate 12a. It can be seen that only intermediate 12 can proceed to form the cyclization products 13 and 13a.
Figure 5The aldol condensation and possible complications.
Enolization of both the aldehyde and the ketone carbonyl groups is possible, while only the cyclization through the ketone carbonyl group enolization can provide the desired product, which is thermodynamically more stable than the other isomer.
Figure 6The synthesis of (+)-gelsemine.
Reagents and conditions: (a) Cat. (0.1 eq), CH3CN/H2O (20:1), −20 °C, 36 h, then NaBH4 (1 eq), 0 °C, 30% for 3a, 47% for 3; (b) DBU, toluene, reflux, 20 h, 97%; (c) Dibal-H (1.05 eq), DCM, −78 °C, 3 h, 90%; (d) KHMDS (4.4 eq), MOMPPh3Cl (4 eq), THF, 0 °C—rt, 3 h, then 4, 0 °C, 4 h; pTSA (0.1 eq), CH(OMe)3, DCM, rt, 93% for 5a and 5 (5a:5=1:13); (e) pTSA (0.1 eq), CH(OMe)3, DCM, rt; (f) O3, DCM, −78 °C, 30 min; NaOCH3 (0.3 eq), CH3OH, 0 °C, 24 h, 60%; (g) NaBH4 (1.1 eq), CH3OH, 0 °C, 30 min, 93%; (h) MsCl (3 eq), DMAP (3 eq), Et3N (5 eq), DCM, 0 °C, quantitative; (i) DBU, toluene, reflux, 24 h, 85%; (j) LiAlH4 (1.2 eq), THF, 0 °C, 10 h, 86%; (k) 6 M HCl, THF, H2O, 3 h, 96%; (l) piperidine, 1-MOM-oxindole (1.5 eq), CH3OH, reflux, 86%; (m) LDA (1.2 eq), Et2AlCl (5 eq), toluene, 32%; (n) 6 M HCl, THF, 50 °C, 24 h; Et3N, CH3OH, 55 °C, 24 h, 70%. DBU, 1,8-diazabicycloundec-7-ene; Dibal-H, diisobutyl aluminium hydride; KHMDS, potassium hexamethyldisilazane; pTSA, p-toluenesulfonic acid; DCM, dichloromethane; MsCl, methanesulfonyl chloride; DMAP, 4-dimethylaminopyridine; LDA, lithium diisopropylamide; rt, room temperature.
Figure 7Intermediates leading to the formation of 3 and 3a.
The reaction consequence indicates that the carbon–carbon double-bond isomerization of the iminium salt occurred at a rate comparable to that of the cycloaddition.
Figure 8The X-ray crystallographic structure of intermediate 8.
ORTEPs are included in the Supporting Information as a separate file. CCDC 1056043 contains the supplementary crystallographic data.